Tag #Wegovy

Showing 37 to 48 of 68 results

es.euronews.com

🌐 85% Global Worthiness

May 1, 19:18

Semaglutide Shows Promise in Treating Metabolic-Associated Fatty Liver Disease

A new study published in the New England Journal of Medicine reveals that semaglutide, a key ingredient in popular weight-loss drugs, significantly improved liver inflammation and scarring in patients with metabolic-associated fatty liver disease (MASH) after 72 weeks, with 33% of patients on semagl...

Semaglutide Shows Promise in Treating Metabolic-Associated Fatty Liver Disease

A new study published in the New England Journal of Medicine reveals that semaglutide, a key ingredient in popular weight-loss drugs, significantly improved liver inflammation and scarring in patients with metabolic-associated fatty liver disease (MASH) after 72 weeks, with 33% of patients on semagl...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What role did lifestyle interventions play in the study's outcomes, and how does this affect the interpretation of semaglutide's impact?

The positive results from this advanced-stage clinical trial, funded by Novo Nordisk, suggest semaglutide could be a viable treatment for MASH, a condition linked to obesity, type 2 diabetes, and hypertension. While lifestyle changes also played a role (34% of the placebo group saw reduced inflammation), semaglutide's impact on both inflammation and scarring was substantially greater. This highlights the potential for a dual approach combining medication with lifestyle interventions.

forbes.com

🌐 75% Global Worthiness

Apr 30, 13:13

HIMS Stock Surges 23% on Wegovy Partnership

Hims & Hers Health (HIMS) stock surged 23% on April 29th after Novo Nordisk announced it would offer its weight-loss drug Wegovy through HIMS's platform, significantly boosting HIMS's revenue potential due to its large subscriber base and the high price of Wegovy.

HIMS Stock Surges 23% on Wegovy Partnership

Hims & Hers Health (HIMS) stock surged 23% on April 29th after Novo Nordisk announced it would offer its weight-loss drug Wegovy through HIMS's platform, significantly boosting HIMS's revenue potential due to its large subscriber base and the high price of Wegovy.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this partnership address previous uncertainties about Hims & Hers Health's long-term strategy?

The partnership between HIMS and Novo Nordisk exemplifies the growing trend of telehealth platforms expanding into specialized healthcare areas like weight management. HIMS's strong subscriber base and the high price point of Wegovy are key factors driving the expected revenue increase. This strategic move solidifies HIMS's position in the market and addresses past concerns about its business model.

forbes.com

🌐 85% Global Worthiness

Mar 17, 22:12

High Cost of GLP-1 Weight Loss Drugs Limits Cost-Effectiveness

A JAMA Health Forum study found that despite improved health outcomes, GLP-1 weight loss medications like Wegovy and Zepbound are not currently cost-effective due to high net prices, patient non-persistence, and insurer churn; price reductions of 30% for tirzepatide and 82% for semaglutide are neede...

High Cost of GLP-1 Weight Loss Drugs Limits Cost-Effectiveness

A JAMA Health Forum study found that despite improved health outcomes, GLP-1 weight loss medications like Wegovy and Zepbound are not currently cost-effective due to high net prices, patient non-persistence, and insurer churn; price reductions of 30% for tirzepatide and 82% for semaglutide are neede...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What long-term strategies could improve the cost-effectiveness and equitable access of GLP-1 medications for obesity?

The lack of cost-effectiveness, coupled with high patient non-persistence (15-25% remaining on treatment after two years), poses challenges for insurers. Despite potential long-term savings from reduced comorbidities, the upfront costs and high patient churn rate make these drugs financially difficult to justify, especially considering Medicare price negotiations and high disenrollment rates may not fully solve these problems. The absence of observed medical cost offset further complicates the issue.

theguardian.com

🌐 85% Global Worthiness

Feb 17, 19:09

Wegovy Approved for Heart Disease Treatment in Australia

Australia's TGA approved Wegovy (semaglutide) in December 2024 for treating cardiovascular disease in overweight and obese adults, reducing heart attack/stroke risk by 20% in a 17,604-person Select trial, but PBS listing remains undecided due to cost.

Wegovy Approved for Heart Disease Treatment in Australia

Australia's TGA approved Wegovy (semaglutide) in December 2024 for treating cardiovascular disease in overweight and obese adults, reducing heart attack/stroke risk by 20% in a 17,604-person Select trial, but PBS listing remains undecided due to cost.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the Select trial contribute to Wegovy's expanded indication, and what were its key findings?

The approval is based on the Select trial's results, showing Wegovy's efficacy in reducing cardiovascular events even in patients without diabetes. This expands the therapeutic potential of GLP-1 RAs beyond their initial diabetes indication, highlighting their impact on inflammation, blood lipids, and blood pressure.

cnbc.com

🌐 75% Global Worthiness

Feb 4, 22:10

GLP-1 Drug Adherence: Cost, Side Effects, and Income Disparities

A JAMA Network Open study reveals that 65% of patients without diabetes stopped using GLP-1 weight loss drugs within a year, compared to 46% of those with Type 2 diabetes; side effects and cost were the main reasons, while higher income and weight loss correlated with continued use; Noom's layoffs e...

GLP-1 Drug Adherence: Cost, Side Effects, and Income Disparities

A JAMA Network Open study reveals that 65% of patients without diabetes stopped using GLP-1 weight loss drugs within a year, compared to 46% of those with Type 2 diabetes; side effects and cost were the main reasons, while higher income and weight loss correlated with continued use; Noom's layoffs e...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does income influence GLP-1 medication adherence, and what are the broader implications for healthcare access and equity?

The study highlights the significant impact of cost and side effects on GLP-1 drug adherence. The findings suggest that factors beyond diabetes status, such as income and weight management, influence treatment persistence. This underscores the need for strategies addressing both patient access and long-term weight maintenance.

dw.com

🌐 75% Global Worthiness

Jan 31, 22:08

Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study

A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.

Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study

A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings of this study regarding the impact of Ozempic and Wegovy on various health risks?

A large-scale study of 1.2 million medical records indicates that popular diabetes and weight-loss drugs, Ozempic and Wegovy, may reduce the risk of other diseases, including schizophrenia and Alzheimer's, by 18% and 12%, respectively. The study also showed a 10% reduction in suicidal thoughts or self-harm.

abcnews.go.com

🌐 85% Global Worthiness

May 1, 04:13

Wegovy Ingredient Shows Promise in Treating Fatty Liver Disease

Research published in the New England Journal of Medicine shows that semaglutide, the active ingredient in Wegovy, significantly reduced liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH), a fatty liver disease affecting an estimated 1.5% to 6.5%...

Wegovy Ingredient Shows Promise in Treating Fatty Liver Disease

Research published in the New England Journal of Medicine shows that semaglutide, the active ingredient in Wegovy, significantly reduced liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH), a fatty liver disease affecting an estimated 1.5% to 6.5%...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of semaglutide's effectiveness in reducing liver inflammation and scarring in patients with MASH?

New research shows the Wegovy active ingredient, semaglutide, significantly reduced liver inflammation in about two-thirds and scarring in one-third of patients with MASH, a fatty liver disease affecting 1.5% to 6.5% of U.S. adults. Patients also lost an average of 8.5% of their body weight over 72 weeks. This is important because MASH can lead to liver failure, cancer, and death.

forbes.com

🌐 85% Global Worthiness

Mar 21, 16:11

Decreased Insurance Coverage for GLP-1 Agonists Amidst Soaring Demand

Between 2024 and 2025, insurance coverage for Ozempic dropped 22%, affecting 1.1 million people, while Zepbound saw a 14% increase in uninsured individuals (4.9 million), despite a 300% rise in Zepbound fills and doubled Ozempic fills since early 2024, highlighting the rising cost of these medicatio...

Decreased Insurance Coverage for GLP-1 Agonists Amidst Soaring Demand

Between 2024 and 2025, insurance coverage for Ozempic dropped 22%, affecting 1.1 million people, while Zepbound saw a 14% increase in uninsured individuals (4.9 million), despite a 300% rise in Zepbound fills and doubled Ozempic fills since early 2024, highlighting the rising cost of these medicatio...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the rising demand and high costs of GLP-1 agonists interact with insurance coverage trends?

The decreased insurance coverage correlates with rising demand for GLP-1 agonists like Ozempic and Zepbound, driven by their weight-loss effects. GoodRx data shows a 300% increase in Zepbound fills and a doubling of Ozempic fills since early 2024. This increase in demand, coupled with high costs (Ozempic: $997.58, Zepbound: $1086.37 per injection pen), creates financial strain for patients.

dailymail.co.uk

🌐 85% Global Worthiness

Mar 17, 16:10

Weight-Loss Injections Linked to Increased Gallbladder Surgery Risk

Pharmacist Deborah Grayson warns of a rise in gallbladder surgeries among patients using weight-loss injections like Mounjaro, attributing the increased risk of gallstones to the drug's mechanism of slowing bile flow; this affects up to 10 percent of users, necessitating greater patient awareness an...

Weight-Loss Injections Linked to Increased Gallbladder Surgery Risk

Pharmacist Deborah Grayson warns of a rise in gallbladder surgeries among patients using weight-loss injections like Mounjaro, attributing the increased risk of gallstones to the drug's mechanism of slowing bile flow; this affects up to 10 percent of users, necessitating greater patient awareness an...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What underlying mechanisms of these weight-loss injections contribute to the increased risk of gallstone formation?

Grayson's observations connect the mechanism of weight-loss injections (slowing bile flow) to a significant complication: gallstone formation. This complication, affecting a substantial portion of Mounjaro users, necessitates increased patient awareness. The higher incidence in users of Mounjaro, compared to similar drugs, warrants further investigation into formulation differences or patient selection.

theguardian.com

🌐 75% Global Worthiness

Feb 12, 04:11

UK Insurer Vitality Offers Discounted Weight Loss Medication

Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.

UK Insurer Vitality Offers Discounted Weight Loss Medication

Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Vitality's new weight loss treatment discount program on its members and the UK healthcare system?

Vitality, the UK's third-largest health insurer, now offers its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro. Eligibility is based on BMI and related health conditions, accessible via the Vitality app. This initiative aims to combat the rising costs of obesity to the NHS, estimated at £6.5 billion annually.

liberation.fr

🌐 75% Global Worthiness

Feb 3, 19:11

France Secures Continued Wegovy Access Pending Price Negotiation

Novo Nordisk will continue providing free Wegovy to 3,000 French patients until at least December 2025 while negotiating a price for national reimbursement, following a positive review by the Haute Autorité de santé (HAS) in December 2024 and initial access for nearly 10,000 patients through an earl...

France Secures Continued Wegovy Access Pending Price Negotiation

Novo Nordisk will continue providing free Wegovy to 3,000 French patients until at least December 2025 while negotiating a price for national reimbursement, following a positive review by the Haute Autorité de santé (HAS) in December 2024 and initial access for nearly 10,000 patients through an earl...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What factors contributed to the decision to provide continued access to Wegovy before official reimbursement?

Novo Nordisk's commitment ensures ongoing treatment for existing patients while France prepares for Wegovy's potential inclusion in its national healthcare system. The drug's high effectiveness (15% average weight loss) and the positive review by the Haute Autorité de santé (HAS) support its case for reimbursement. This follows an earlier program providing access to nearly 10,000 patients.

dw.com

🌐 75% Global Worthiness

Jan 28, 22:12

GLP-1 RA Drugs Show Promise, but Limitations Remain

A study of 1.2 million medical records found that GLP-1 RA drugs, such as Ozempic and Wegovy, may reduce the risk of several health issues, including substance use disorders, psychiatric disorders, and dementia, by 8-18%, but also carry risks of nausea, vomiting, and pancreatic or kidney complicatio...

GLP-1 RA Drugs Show Promise, but Limitations Remain

A study of 1.2 million medical records found that GLP-1 RA drugs, such as Ozempic and Wegovy, may reduce the risk of several health issues, including substance use disorders, psychiatric disorders, and dementia, by 8-18%, but also carry risks of nausea, vomiting, and pancreatic or kidney complicatio...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the broader systemic implications of this study's findings considering its limitations in sample representation and study design?

The study focused on GLP-1 receptor agonists (GLP-1 RAs), a class of drugs that includes Ozempic and Wegovy. These drugs affect brain receptors involved in impulse control, reward, and addiction, potentially explaining their impact on appetite and addiction disorders. The observed benefits were linked to the drugs' ability to reduce blood glucose levels and slow intestinal emptying.

Showing 37 to 48 of 68 results